Neomycin Sulfate Injection

1 Pharmacology: This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6') produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the 30S subunit of bacterial ribosomes and inhibit the synthesis of bacterial proteins. 2 Toxicology: Acute toxicity: The median lethal dose (LD50) of this product for intravenous injection is 78.9 mg/kg, and the LD50 for intramuscular injection is 286 plus mn; 19.7 mg/kg. Chronic toxicity: Experiments were conducted on healthy male Wistar rats (weight 200 plus mn; 20g). The results showed that even if a large dose of this product (156 mg/kg) was injected intramuscularly for 30 consecutive days, the animals could survive; although the animals sometimes showed signs of malaise and loss of appetite 7 to 10 days after the injection, the reaction improved in the later stage of the injection, and the activity returned to normal after the drug was stopped. Renal and ototoxicity: The research results of the Pharmacology Teaching and Research Section of Nanjing Medical College show that the renal toxicity of this product is relatively mild. When a large dose (156 mg/kg) is administered, only obvious vacuolar degeneration of renal epithelial cells is observed, and no other special lesions are found. After the drug is administered to guinea pigs (10), there are no changes in hearing and vestibular function. After the animals are sacrificed and cochlear spreads are made, the cochlear hair cells of 7 guinea pigs are completely normal, and only a few cochlear hair cells of the other 3 are necrotic (10, 10, and 17 respectively).

The main component of this product is streptavidin sulfate. Its chemical name is O-2-amino-2,3,4,5-tetradeoxy-5-(methylamino)-2-d-erythro-hexopyranosyl-(1rarr;4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-?-L-arabinopyranosyl-(1rarr;6)-2-deoxy-d-streptamine sulfate.

This product is a colorless or almost colorless clear liquid.

This product is mainly used for respiratory tract, urinary tract, abdominal cavity and trauma infections caused by Gram-negative bacteria such as Escherichia coli, Klebsiella, Proteus, Enterobacter, Serratia, Pseudomonas aeruginosa, etc. It can also be used for sepsis.

Intramuscular injection or intravenous drip after dilution. Intramuscular injection for adults: 60-80 mg at a time, up to 120 mg if necessary, 2-3 times a day; intravenous drip: 60 mg at a time, add to 100 ml of sodium chloride injection and drip at a constant speed, and the drip should be completed within 1 hour. Children should be given 3-4 mg/kg of body weight in 2-3 doses.

1Common symptoms include hearing loss, tinnitus or fullness in the ears (ototoxicity), hematuria, significantly reduced frequency of urination or decreased urine volume, loss of appetite, extreme thirst (nephrotoxicity), unsteady gait, dizziness (ototoxicity, vestibular effects), nausea or vomiting (ototoxicity, vestibular effects, nephrotoxicity). 2Rare symptoms include vision loss (optic neuritis), dyspnea, drowsiness, extreme weakness (neuromuscular blockade), allergic reactions such as rashes, changes in blood counts, changes in liver function, digestive tract reactions, pain at the injection site, nodules, phlebitis, etc. 3Rarely, anaphylactic shock.

1. Patients who are allergic to this product or other aminoglycosides and bacitracin, or who have family members who have developed deafness or other hearing loss due to the use of streptomycin are contraindicated. 2. Patients with renal failure are contraindicated.

1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used with other aminoglycosides or when applied topically or systemically one after the other. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used topically or systemically with cephalothin. 4 This product should not be used in combination with polymyxins, or applied topically or systemically in sequence, because it can increase nephrotoxicity and neuromuscular blocking effects, the latter of which can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5 This product should not be used in combination with other nephrotoxic or ototoxic drugs, or applied sequentially, so as not to aggravate nephrotoxicity or ototoxicity. 6 This product should not be used in combination with amphotericin B, cephalothin sodium, nitrofurantoin sodium, sulfadiazine sodium and tetracycline hydrochloride (all of the above are injections), because incompatibility may occur. 7 This product can often achieve synergistic effects when used in combination with beta-lactams (cephalosporins or penicillins). 8 This product mixed with beta-lactams (cephalosporins or penicillins) can lead to mutual inactivation, and must be dripped in separate bottles when used in combination.

Keep tightly closed in a cool, dark place.

2ml: 80000 units

Jilin Century Hanke Pharmaceutical Co., Ltd.

• Founded in:

  2011-06-29

• Address:

  No. 255, Songyuan Avenue, Songyuan City

• Tax NO.:

  91220701574088902W

• Registered Funds:

  92.25 million yuan

• Email:

  Log in to view